These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 3226945)

  • 21. [A study on experimental mycobacterioses provoked by atypical mycobacteria. 2. Combined antituberculous chemotherapy against conventional mice infected intravenously with Mycobacterium intracellulare (author's transl)].
    Kuze F; Lee Y; Maekawa N; Suzuki Y
    Kekkaku; 1979 Sep; 54(9):453-60. PubMed ID: 502152
    [No Abstract]   [Full Text] [Related]  

  • 22. Response to chemotherapy of pulmonary infection due to mycobacterium kansasii.
    Harris GD; Johnason WG; Nicholson D
    Bull Int Union Tuberc; 1976; 51(1):275-8. PubMed ID: 1030296
    [No Abstract]   [Full Text] [Related]  

  • 23. The clearance of theophylline is increased during the initial period of tuberculosis treatment.
    Ahn HC; Lee YC
    Int J Tuberc Lung Dis; 2003 Jun; 7(6):587-91. PubMed ID: 12797703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Results of initial treatment of pulmonary tuberculosis using ethambutol, isonicotinic acid hydrazide and rifampicin].
    Kesztele V; Niederkofler J
    Wien Med Wochenschr; 1970 Jun; 120(25):473-5. PubMed ID: 5518004
    [No Abstract]   [Full Text] [Related]  

  • 25. [Sensitivity of m. kansasii strains to various antibiotics and chemotherapeutics in vitro and in vivo (author's transl)].
    Burjanová B; Dornetzhuber V
    Z Erkr Atmungsorgane; 1975 Jan; 142(1):68-77. PubMed ID: 58490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug resistance of Mycobacterium tuberculosis strains isolated from patients with pulmonary tuberculosis in Archangels, Russia.
    Toungoussova S; Caugant DA; Sandven P; Mariandyshev AO; Bjune G
    Int J Tuberc Lung Dis; 2002 May; 6(5):406-14. PubMed ID: 12019916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synergistic activity of rifampicin and ethambutol against slow-growing nontuberculous mycobacteria is currently of questionable clinical significance.
    van Ingen J; Hoefsloot W; Mouton JW; Boeree MJ; van Soolingen D
    Int J Antimicrob Agents; 2013 Jul; 42(1):80-2. PubMed ID: 23664674
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Activity of the second-line preparations, ethambutol and rifampin, in experimental tuberculosis caused by Mycobacterium tuberculosis highly resistant to basic tuberculostatics].
    Golyshevskaia VI; El'shanskaia MP
    Probl Tuberk; 1973; 51(12):60-4. PubMed ID: 4205666
    [No Abstract]   [Full Text] [Related]  

  • 29. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
    Lu T; Drlica K
    J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis.
    Bhusal Y; Shiohira CM; Yamane N
    Int J Antimicrob Agents; 2005 Oct; 26(4):292-7. PubMed ID: 16150578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-resistant tuberculosis in Budapest.
    Fodor T; Vadász I; Lõrinczi I
    Int J Tuberc Lung Dis; 1998 Sep; 2(9):732-5. PubMed ID: 9755927
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of initial drug resistance to M. tuberculosis in new sputum positive RNTCP patients.
    Dhingra VK; Rajpal S; Bhalla P; Yadav A; Jain SK; Hanif M
    J Commun Dis; 2003 Jun; 35(2):82-9. PubMed ID: 15562953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The resistance rates of Mycobacterium tuberculosis strains to antituberculosis drugs: evaluation of two years' data in Aegean region, Turkey].
    Güneri S; Unsal I; Oztop A; Erkut M; Avkan Oğuz V; Ozgü A; Cakmak R
    Mikrobiyol Bul; 2004 Jul; 38(3):203-12. PubMed ID: 15490839
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A case of Mycobacterium kansasii lung infection developed after treatment of Mycobacterium gordonae lung infection].
    Umeki S; Okamoto Y; Hara Y
    Kekkaku; 1988 Dec; 63(12):785-90. PubMed ID: 3226033
    [No Abstract]   [Full Text] [Related]  

  • 35. [Drug sensitivity of the so-called atypical mycobacteria].
    Lucchesi M; Mancini P; Matzeu M
    Ann Ist Carlo Forlanini; 1968; 28(1):25-41. PubMed ID: 4314838
    [No Abstract]   [Full Text] [Related]  

  • 36. Combined versus single antituberculosis drugs on the in vitro sensitivity patterns of non-tuberculous mycobacteria.
    Banks J; Jenkins PA
    Thorax; 1987 Nov; 42(11):838-42. PubMed ID: 3424264
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Drug sensitivity of atypical Mycobacteria isolated from patients to antitubercular agents of the first and second order].
    Makarevich NM; Rudoĭ NM
    Antibiotiki; 1971 Feb; 16(2):149-52. PubMed ID: 4326726
    [No Abstract]   [Full Text] [Related]  

  • 38. [Therapeutic results in lung diseases caused by atypical mycobacteria].
    Fischer P; Schilling W
    Z Erkr Atmungsorgane; 1984; 162(1):26-9. PubMed ID: 6202070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug susceptibility testing and pharmacokinetics question current treatment regimens in Mycobacterium simiae complex disease.
    van Ingen J; Totten SE; Heifets LB; Boeree MJ; Daley CL
    Int J Antimicrob Agents; 2012 Feb; 39(2):173-6. PubMed ID: 22099521
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro testing of clarithromycin in combination with ethambutol and rifampicin against Mycobacterium avium complex.
    Stauffer F; Dörtbudak O; Lahonik E
    Infection; 1991; 19(5):343-5. PubMed ID: 1839300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.